Familial Hypercholesterolemia and Premature Atherosclerosis

Pathophysiology and Clinical Presentation

• Familial Hypercholesterolemia (FH) is a co-dominant and highly penetrant monogenic disorder characterized by markedly elevated LDL-cholesterol concentrations from birth, which if untreated, inevitably leads to premature atherosclerotic cardiovascular disease (ASCVD) 1, 2
• The American Heart Association notes that FH results from defects in the hepatic LDL clearance pathway, most commonly involving mutations in LDLR, APOB, and PCSK9 genes, leading to impaired clearance of circulating LDL particles 3
• The Pathobiological Determinants of Atherosclerosis in Youth Study (PDAY) and the Bogalusa Heart Study demonstrated that every 0.26–0.39 mmol/L (10–15 mg/dL) increase in non-HDL cholesterol is associated with an additional year of vascular aging 4
• A 15-year-old with heterozygous FH essentially has the same amount of atherosclerosis as a 20–35 year old with average lipid profile, depending on additional risk factors 4

Evidence from Genetic Studies

• Mendelian randomization studies of common DNA polymorphisms with effects on LDL cholesterol provide strong evidence for a causative role of LDL in cardiovascular disease 4
• Genetic variants at PCSK9, HMGCR, and NPC1L1 loci that specifically associate with LDL cholesterol also predict coronary heart disease risk 4
• Studies have shown that loss of function mutations in PCSK9 are associated with reduced LDL cholesterol and substantial reductions in coronary heart disease risk 4

Diagnosis and Public Health Impact

• The American College of Cardiology notes that clinical diagnosis of FH relies on elevated LDL-cholesterol concentrations, family history of premature coronary artery disease, and physical stigmata such as tendon xanthomas 5
• In children, clinical diagnosis depends on elevated LDL-cholesterol concentrations and a positive family history of premature coronary artery disease and/or high LDL-cholesterol concentration in at least one parent 5
• FH affects approximately 1 in 311 people in the general population, potentially impacting up to 35 million people worldwide 1, 2
• Only about 10% of FH cases are currently diagnosed, and >80% of those treated do not achieve recommended LDL-cholesterol goals 1, 2

Familial Hypercholesterolemia and Atherosclerosis Risk

Understanding FH and Atherosclerosis Risk

• Familial Hypercholesterolemia (FH) is a co-dominant and highly penetrant monogenic disorder characterized by markedly elevated LDL-cholesterol concentrations from birth, which if untreated, typically leads to premature atherosclerotic cardiovascular disease (ASCVD), affecting approximately 1 in 311 people in the general population, potentially impacting up to 35 million people worldwide 6
• FH results from genetic defects in the hepatic LDL clearance pathway, most commonly involving mutations in LDLR, APOB, PCSK9, or LDLRAP1 genes 7

Factors That May Explain Absence of Atherosclerosis in Some FH Patients

Genetic Factors

• Different mutations in FH-causing genes can result in varying degrees of LDL receptor dysfunction 7

Lifestyle and Intervention Factors

• Diet, exercise, and absence of other cardiovascular risk factors (smoking, hypertension, diabetes) may play protective roles 8
• Early diagnosis and aggressive treatment with lipid-lowering therapies, such as statins, ezetimibe, PCSK9 inhibitors, can significantly alter the natural history of FH and effectively lower LDL-C levels and prevent or delay atherosclerosis development 8

Clinical Implications

• The International Atherosclerosis Society recommends Doppler echocardiographic evaluation of the heart and aorta annually, and computed tomography coronary angiography every 5 years or less if deemed necessary 8
• Risk stratification should include genetic testing whenever possible to confirm the diagnosis and identify the specific mutation, as recommended by guideline societies such as the International Atherosclerosis Society 7, 9

Management of Familial Hypercholesterolemia

Treatment Approach

• The American College of Cardiology recommends that all Familial Hypercholesterolemia (FH) patients require aggressive cholesterol-lowering therapy regardless of current atherosclerosis status, as the lifetime risk remains high 10
• Treatment should begin with high-intensity statins, adding ezetimibe and PCSK9 inhibitors as needed to achieve LDL-C goals, as recommended by the American Heart Association 11
• Combination therapies including high-intensity statins, ezetimibe, and PCSK9 inhibitors can effectively lower LDL-C levels and prevent or delay atherosclerosis development, according to the European Atherosclerosis Society 10, 11
• For those with homozygous FH or treatment-resistant heterozygous FH with established atherosclerotic cardiovascular disease (ASCVD), lipoprotein apheresis should be considered, as suggested by the International Atherosclerosis Society 12

Risk Stratification and Monitoring

• Low HDL-cholesterol is a key risk factor for ASCVD in FH patients, as identified by the American College of Cardiology 12
• CT coronary angiography, carotid ultrasonography, and echocardiography can be used to assess the presence and severity of subclinical atherosclerosis, as recommended by the European Society of Cardiology 11
• Coronary artery calcium scoring (CACS) is useful in initial risk assessment but should not be used to monitor treatment effectiveness, according to the American Heart Association 11
• Regular cardiovascular imaging is recommended to assess for development or progression of atherosclerosis, as suggested by the International Atherosclerosis Society 11

Clinical Implications

• Early diagnosis and aggressive treatment with lipid-lowering therapies can significantly alter the natural history of FH, as reported by the American College of Cardiology 10
• Underestimating the importance of early intervention can lead to silent atherosclerosis progression, as studies show that earlier treatment leads to greater reduction in ASCVD events, according to the European Atherosclerosis Society 10

Familial Hypercholesterolemia Diagnosis and Genetic Testing

Importance of Accurate Diagnosis

• Genetic testing is the most accurate way to diagnose Familial Hypercholesterolemia (FH) and should be performed in all suspected cases to confirm diagnosis, enable cascade testing of family members, and guide appropriate treatment decisions 13
• Clarifying FH enables identification of affected family members through cascade testing, which is highly cost-effective 14

Diagnostic Approach

• In adults, the most widely used clinical diagnostic methods are the Dutch Lipid Clinic Network and the Simon Broome criteria 13, 15

Genetic Testing Requirements

• Genetic testing identifies pathogenic variants in genes that impair LDL receptor function, providing the most accurate diagnosis of FH 13
• Testing should focus on the three most common causative genes: LDLR, APOB, and PCSK9 15
• Comprehensive genetic testing should be performed in index cases with suspected FH to identify the specific pathogenic variant 16, 14

Implementation of Genetic Testing

• Pre-test and post-test genetic counseling should be offered to all patients and at-risk relatives as an integral component of testing 14, 17
• After identifying a pathogenic variant in the proband, cascade genetic testing for the specific variant should be offered to all first-degree relatives, then second-degree and third-degree relatives if needed 14

Common Pitfalls and Caveats

• Genetic testing is currently underutilized due to costs, inadequate clinical skills in genomic medicine, genetic privacy concerns, and limited availability of genetic counseling services 18, 17
• Adjustment for concurrent lipid-lowering medications is required to make an accurate phenotypic diagnosis 13
• Polygenic scores for hypercholesterolemia are not yet fully standardized and should be used with caution when assessing the differential diagnosis of FH 14
• A pathogenic variant may not be found in all clinically diagnosed FH cases due to polygenic hypercholesterolemia or unidentified pathogenic variants 17

Diagnosis and Management of Familial Hypercholesterolemia

Clinical Diagnosis and Diagnostic Criteria

• The American College of Cardiology recommends using the Dutch Lipid Clinic Network or Simon Broome criteria to establish clinical diagnosis in adults, which incorporate LDL-C levels, family history of premature coronary artery disease, and physical stigmata such as tendon xanthomas 19
• The European Atherosclerosis Society suggests that LDL-C ≥190 mg/dL (≥4.9 mmol/L) in adults without secondary causes strongly suggests FH and warrants phenotypic screening of first-degree relatives 19
• The American Heart Association states that in children, diagnosis relies on elevated LDL-C plus positive family history of premature coronary disease or high LDL-C in at least one parent 19

Management and Treatment

• The American College of Cardiology recommends initiating high-intensity statin therapy (rosuvastatin 20-40 mg or atorvastatin 40-80 mg) as first-line treatment for patients with FH 20
• The American College of Cardiology suggests targeting LDL-C <100 mg/dL (2.6 mmol/L), or <70 mg/dL (1.8 mmol/L) if atherosclerotic cardiovascular disease is present 20
• The European Atherosclerosis Society recommends adding ezetimibe if <50% LDL-C reduction or target not achieved on maximally tolerated statin 20
• The American College of Cardiology considers PCSK9 inhibitors if LDL-C remains ≥70 mg/dL despite statin plus ezetimibe 20

Management of Familial Hypercholesterolemia

Guideline-Based Recommendations

• The International Atherosclerosis Society recommends that all patients with suspected familial hypercholesterolemia (FH) should be referred to, or discussed with, a relevant specialist to plan further management and care, which is a Class 1 recommendation, representing the highest level of evidence-based guidance 21, 22
• National and regional centers with expertise in lipidology, genetics, and atherosclerotic cardiovascular disease (ASCVD) prevention should be established to accept referrals and give advice, as the complexity of FH management requires specialized knowledge that extends beyond routine primary care 21, 22
• The American College of Cardiology and other guideline societies support the concept that specialist-led care is crucial for optimal management of FH, including genetic confirmation, complex treatment decisions, and specialized centers for severe cases 21, 22

Clinical Implications for Morbidity and Mortality

• FH leads to premature ASCVD if untreated: by age 50, 50% of men and 25% of women with untreated FH will experience clinical cardiovascular disease, highlighting the need for early diagnosis and treatment 23
• Early diagnosis and aggressive treatment with lipid-lowering therapies can significantly alter the natural history of FH, reducing ASCVD events, which is a key objective of specialist-led care 21, 22

Multidisciplinary Care Model

• A multidisciplinary team with expertise in caring for individuals with FH should partner with primary care and include representation from appropriate specialty disciplines, including mental health care, to ensure comprehensive management 21, 22
• Primary care remains actively involved in screening, diagnosing, managing cholesterol-lowering therapy, addressing comorbidities, and providing regular review, while specialists provide the expertise for genetic counseling, advanced treatment options, and management of treatment-resistant cases 21, 22

Risks of Untreated High Cholesterol

Cardiovascular Disease Risk and Mortality

• By age 50, untreated familial hypercholesterolemia results in clinical cardiovascular disease in 50% of men and 25% of women, with coronary artery disease mortality being substantially elevated in adults younger than 60 years 24
• Untreated familial hypercholesterolemia is associated with ischemic heart disease in 1 in 6 men and 1 in 10 women by age 40 years 24
• Coronary artery disease occurs in 50% of men by age 50 years and 30% of women by age 60 years with untreated familial hypercholesterolemia 24

Specific Cardiovascular Events

• The American College of Cardiology identifies myocardial infarction as a specific risk of untreated hypercholesterolemia 25
• The American College of Cardiology also identifies hospitalization for congestive heart failure as a risk of untreated hypercholesterolemia 25
• The American College of Cardiology identifies unstable and stable angina requiring medical management as a risk of untreated hypercholesterolemia 25
• Stroke risk increases proportionally with LDL cholesterol levels, according to the European Heart Journal 26

Risk Amplification

• Family history of high cholesterol suggests possible genetic hypercholesterolemia, which places individuals at high total cardiovascular risk, according to the European Heart Journal 26
• Physical inactivity compounds the risk by reducing HDL cholesterol and promoting metabolic syndrome, according to the European Heart Journal 27
• Diet high in saturated fats directly elevates LDL cholesterol levels and promotes inflammatory changes in arterial walls, according to Circulation 28
• When family history, physical inactivity, and diet high in saturated fats coexist, the 10-year cardiovascular death risk typically exceeds 5%, warranting immediate intensive intervention, according to the European Heart Journal 26, 27

Critical Threshold Levels

• Total cholesterol >8 mmol/L (320 mg/dL) and LDL cholesterol >6 mmol/L (240 mg/dL) places individuals at high total cardiovascular risk, especially when elevated since childhood, according to the European Heart Journal 26
• HDL cholesterol <1.0 mmol/L (40 mg/dL) in men and <1.2 mmol/L (46 mg/dL) in women serves as a marker of increased cardiovascular risk, according to the European Heart Journal 26, 27
• Fasting triglycerides >1.7 mmol/L (150 mg/dL) indicate increased cardiovascular risk, according to the European Heart Journal 26, 27

Preventable Burden

• The burden of untreated hypercholesterolemia is entirely attributable to premature cardiovascular events in adulthood resulting from long-term exposure to elevated cholesterol levels and progressive atherosclerosis, according to the American Family Physician 24
• Early identification and aggressive treatment with lipid-lowering therapies can significantly alter the natural history and reduce ASCVD events, according to the Journal of the American College of Cardiology 25
• The relative risk reduction from statin therapy is consistent across all baseline LDL cholesterol levels ≥70 mg/dL, but absolute risk reduction is proportional to baseline absolute ASCVD risk, according to the Journal of the American College of Cardiology 25